NEW YORK (GenomeWeb) – Belgian diagnostics firm VolitionRx said today that it has acquired a patent family around nucleosome analysis in cancer from Chroma Therapeutics.

The patent family, WO 2005/019826, was originally filed by UK-based Chroma and exclusively licensed to VolitionRx.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.